Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytokinetics (NQ: CYTK )

51.82 +0.82 (+1.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics

< Previous 1 2 3 4 5 6 7 Next >
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. 
Via InvestorPlace
Masters In Trading - Saturday, March 16
In this snippet from Friday's trading session, I review my various trades from the past week. 
Via Talk Markets
Here's How Much $100 Invested In Cytokinetics 10 Years Ago Would Be Worth Today
Via Benzinga
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation. 
Via InvestorPlace
Super Micro, Deckers To Join S&P 500 Index
They'll replace Whirlpool and Zions Bancorp on March 18. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Unpacking the Latest Options Trading Trends in Cytokinetics
Via Benzinga
Here's How Much $1000 Invested In Cytokinetics 10 Years Ago Would Be Worth Today
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
Overbought, Overextended - What's The Buzz In S&P 500 Now?
Here are the red flags you need to be aware of in this current market and the directional bias for the long-term, swing and immediate term. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Here's How Much $1000 Invested In Cytokinetics 5 Years Ago Would Be Worth Today
Via Benzinga
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month. 
Via InvestorPlace
How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month
Cytokinetics is looking to take on Bristol Myers Squibb in treating a heart disease. 
Via Investor's Business Daily
Banco Santander, Lloyds Banking And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Monday. Shares of Banco Santander, S.A. (NYSE: SAN) shares fell sharply during today’s pre-market trading. 
Via Benzinga
Topics Stocks
Exposures US Equities
Here's How Much $100 Invested In Cytokinetics 5 Years Ago Would Be Worth Today
Via Benzinga
3 Healthcare Stocks at 52-Week Lows: Buy or Bye?
Investors should consider picking up these healthcare stocks at 52-week lows to benefit from their potential rebound. 
Via InvestorPlace
Biotech Playbook: Small Caps Show Momentum Peaking During
The momentum of selected stocks was strong up until early January was encouraging but we need less volatility in period ahead to conform a new bull market. 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed... 
Via Benzinga
Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition
Novartis AG (NYSE: NVS) has decided to step back from pursuing the Cytokinetics Inc (NASDAQ: CYTK) acquisition, dealing a blow to the potential deal with the  
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Aspen Aerogels Issues Business Update, Joins Plug Power, SunPower And Other Big Stocks Moving Lower On Thursday
U.S. stocks traded lower, with the Dow Jones index falling over 150 points on Thursday. Shares of Aspen Aerogels, Inc. (NYSE: ASPN) fell sharply during Thursday’s session after the company issued a... 
Via Benzinga
Topics Stocks
Exposures US Equities
Bullish Continuation In '24? 3 Market Areas To Watch
This article discusses 3 market areas that should outperform dramatically over the next 12 months... 
Via Talk Markets
What's Been Happening With Cytokinetics Stock?
Cytokinetics, Incorporated (NASDAQ: CYTK) shares are trading lower on Tuesday, pulling back from Monday strength. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Is Heart Failure Drug-Focused Cytokinetic Stock Trading Higher Today?
Cytokinetics Inc (NASDAQ: CYTK) shares are trading higher after a report on potential takeover talks with Novartis AG (NYSE: NVS). 
Via Benzinga
Cytokinetics Rockets 14% As Novartis Reportedly Nears A Buyout Deal
The company is working on a treatment for a disease that can lead to heart failure. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
CACI International To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
7 Stocks Primed for a Spectacular Comeback in 2024
Although the usual suspects may carry confidence, these underappreciated comeback stocks might deliver the goods in 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.